Ertapenem: Difference between revisions
Gerald Chi (talk | contribs) |
No edit summary |
||
| Line 17: | Line 17: | ||
'''| [[Ertapenem indications and usage|Indications and Usage]]''' | '''| [[Ertapenem indications and usage|Indications and Usage]]''' | ||
'''| [[Ertapenem contraindications|Contraindications]]''' | '''| [[Ertapenem contraindications|Contraindications]]''' | ||
'''| [[Ertapenem warnings|Warnings and Precautions]]''' | '''| [[Ertapenem warnings and precaution|Warnings and Precautions]]''' | ||
'''| [[Ertapenem adverse reactions|Adverse Reactions]]''' | '''| [[Ertapenem adverse reactions|Adverse Reactions]]''' | ||
'''| [[Ertapenem overdosage|Overdosage]]''' | '''| [[Ertapenem overdosage|Overdosage]]''' | ||
Revision as of 14:47, 24 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz®. It is structurally very similar to meropenemin that it possess a 1-β-methyl group.
Category
Carbapenems
US Brand Names
INVANZ®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of action
Ertapenem has in vitro activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichia coli, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3.